Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

Sehgal, Suren N.; Baker, Hinton J.; Vézina, Claude

doi:10.7164/antibiotics.28.727

Cited by 853 publications

(415 citation statements)

References 0 publications

Supporting

Mentioning

398

Contrasting

Unclassified

Order By: Relevance

“…Thus, mTORC1, which was identified in studies aimed at defining the molecular target of the antiproliferative drug rapamycin (10,43,44), serves as a "master" regulator that integrates information from various synaptic inputs to produce an appropriate translational output. However, whether mTORC1 plays a role in memory consolidation remains unclear.…”

Section: Resultsmentioning

confidence: 99%

Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage

Stoica

Zhu²,

Huang³

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

200

156

View full text Add to dashboard Cite

Both the formation of long-term memory (LTM) and late-long-term potentiation (L-LTP), which is thought to represent the cellular model of learning and memory, require de novo protein synthesis. The mammalian target of Rapamycin (mTOR) complex I (mTORC1) integrates information from various synaptic inputs and its best characterized function is the regulation of translation. Although initial studies have shown that rapamycin reduces L-LTP and partially blocks LTM, recent genetic and pharmacological evidence indicating that mTORC1 promotes L-LTP and LTM is controversial. Thus, the role of mTORC1 in L-LTP and LTM is unclear. To selectively inhibit mTORC1 activity in the adult brain, we used a "pharmacogenetic" approach that relies on the synergistic action of a drug (rapamycin) and a genetic manipulation (mTOR heterozygotes, mTOR +/− mice) on the same target (mTORC1). Although L-LTP and LTM are normal in mTOR +/− mice, application of a low concentration of rapamycin-one that is subthreshold for WT mice-prevented L-LTP and LTM only in mTOR +/− mice. Furthermore, we found that mTORC1-mediated translational control is required for memory reconsolidation. We provide here direct genetic evidence supporting the role of mTORC1 in L-LTP and behavioral memory.behavioral learning | pharmacology | fear conditioning

show abstract

Section: Resultsmentioning

confidence: 99%

Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage

Stoica

Zhu²,

Huang³

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

200

156

View full text Add to dashboard Cite

show abstract

“…This natural product was initially described as an antifungal metabolite from Streptomyces hygroscopicus, isolated from a soil sample of the island of Rapa Nui [30]. It was found shortly afterward to have inhibitory activity toward the mammalian immune system [31].…”

Section: Rapamycinmentioning

confidence: 99%

Stabilization of protein–protein interactions by small molecules

Giordanetto¹,

Schäfer

Ottmann

2014

Drug Discovery Today

View full text Add to dashboard Cite

“…It is a well known fact that most of the revolutionary medicines, like Rapa, cyclosporin A, and FK506, exhibiting antibiotic or antifungal properties were later proven to possess potent immunosuppressive activity (21)(22)(23). CaeA is a bipyridyl compound and has been reported in the literature to show antifungal and antibiotic properties (24,25).…”

mentioning

confidence: 99%

Caerulomycin A Enhances Transforming Growth Factor-β (TGF-β)-Smad3 Protein Signaling by Suppressing Interferon-γ (IFN-γ)-Signal Transducer and Activator of Transcription 1 (STAT1) Protein Signaling to Expand Regulatory T Cells (Tregs)

Gurram¹,

Kujur²,

Maurya³

et al. 2014

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Caerulomycin A, a known antifungal agent, was explored for its novel immunomodulatory activity. Results: Caerulomycin A supports the generation of Tregs by augmenting the TGF-␤-Smad3 and suppressing the IFN-␥-STAT1 signaling pathways by enhancing SOCS1 expression. Conclusion: Caerulomycin A induces and enhances the Treg population. Significance: Caerulomycin A can be a potent future drug for treating autoimmune diseases by eliciting the generation of Tregs.

show abstract

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

Abstract: Rapamycin is a new antifungal antibiotic produced by Streptomyces hygroscopicus

Cited by 853 publications

References 0 publications

Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage

Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage

Stabilization of protein–protein interactions by small molecules

Caerulomycin A Enhances Transforming Growth Factor-β (TGF-β)-Smad3 Protein Signaling by Suppressing Interferon-γ (IFN-γ)-Signal Transducer and Activator of Transcription 1 (STAT1) Protein Signaling to Expand Regulatory T Cells (Tregs)

Contact Info

Product

Resources

About